CIK 0001231457
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
GENELUX Corp
Sign in to watch- Ticker
- GNLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 805-267-9889
- Business address
- 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE, CA, 91361
- 4 Derivatives Options or other derivatives
- 4 Grant or award Director acquired 22,283 shares (grant or award)
- 4 Grant or award President and CEO acquired 361,200 shares (grant or award)
- 4 Grant or award Head of Regulatory acquired 26,230 shares (grant or award)
- 4 Grant or award Director acquired 22,283 shares (grant or award)
- 4 Grant or award SVP, Clinical Development acquired 101,480 shares (grant or award)
- 4 Grant or award Director acquired 22,283 shares (grant or award)
- 4 Grant or award Director acquired 22,283 shares (grant or award)
- 4 Grant or award Chief Technical Officer acquired 107,500 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Gift Director gave 25,000 shares (gift)
- 4 Open-market sale General Counsel sold 4,475 shares at $2.92 ($13,067)
- 4 Open-market sale President and CEO sold 10,764 shares at $2.92 ($31,431)
- 4 Open-market sale VP, Clinical Trial Operations sold 5,579 shares at $2.92 ($16,291)
- 4 Open-market sale VP, Pharmaceutical Development sold 4,737 shares at $2.92 ($13,832)
- 4 Open-market sale Head of Regulatory sold 1,259 shares at $2.92 ($3,676)
- 4 Grant or award Head of Regulatory acquired 4,172 shares (grant or award)
- 4 Grant or award VP, Pharmaceutical Development acquired 13,350 shares (grant or award)
- 4 Grant or award VP, Clinical Trial Operations acquired 13,350 shares (grant or award)
Page 3 of 10 · 190 filings